UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000010453
Receipt number R000012219
Scientific Title Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease (PERSEUS)
Date of disclosure of the study information 2013/04/10
Last modified on 2017/01/04 12:12:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease (PERSEUS)

Acronym

Cardiac Progenitor Cell Transfer for Univentricular Heart

Scientific Title

Cardiac Progenitor Cell Infusion to Treat Univentricular Heart Disease (PERSEUS)

Scientific Title:Acronym

Cardiac Progenitor Cell Transfer for Univentricular Heart

Region

Japan


Condition

Condition

Hypoplastic left heart syndrome
Single right ventricle
Single left ventricle

Classification by specialty

Cardiology Vascular surgery Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of this study is to investigate the efficacy of intracoronary infusion of cardiac progenitor cells in patients with univentricular heart disease. Patients with preoperative high-risk group or whose cardiac function did not recover postoperatively eventually have no choice other than heart transplantation.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase II


Assessment

Primary outcomes

The primary outcome measure is to evaluate the cardiac function improvement by echocardiography, ventriculography, and cardiac MRI, which are conducted before and 3 months after surgical treatment.

Key secondary outcomes

The secondary outcome measure is to determine the cardiac function improvements by three different imaging modalities at 12 months after treatment. Clinical symptoms and BNP levels will be assessed at 3- and 12-months after treatment and compared with control group.


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

(Stage 1) single dose, intracoronary infusion of 0.3 million cell/kg cardiac progenitor cells (cell infusion group).

Interventions/Control_2

(Stage 2) Rescuing transplantation is applicable in patients, along with their written consent, 4 months after palliations who were assigned as control group in stage 1.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit

20 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Age: Age is 0 year or more and 20 years or less at the time of patient enrollment.
2) The patients have functional single ventricular physiology with the indication to have stage-2 or -3 palliative surgeries.
3) The ventricular ejection fraction <60%.

Key exclusion criteria

1) Cardiogenic shock
2) A patient with unstoppable extracorporeal circulation
3) A patient with lethal, uncontrollable arrhythmia
4) A patient with a complication of coronary artery disease
5) A patient with a complication of brain dysfunction due to circulatory failure
6) A patient with malignant neoplasm
7) A patient with a complication of serious neurologic disorder
8) A patient with high-grade pulmonary embolism or pulmonary hypertension
9) A patient with high-grade renal failure
10) A patient with multiple organ failure
11) Active infection (including endocarditis)
12) Sepsis
13) Active hemorrhagic disease (e. g. gastrointestinal bleeding, injury)

Target sample size

34


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Hidemasa Oh

Organization

Okayama University Hospital

Division name

Center for Innovative Clinical Medicine

Zip code


Address

2-5-1 Shikata-cho, Kita-ku, Okayama

TEL

+81-086-235-6506

Email

hidemasa@md.okayama-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Hidemasa Oh

Organization

Okayama University Hospital

Division name

Center for Innovative Clinical Medicine

Zip code


Address

2-5-1 Shikata-cho, Kita-ku, Okayama

TEL

+81-086-235-6506

Homepage URL

http://shin-iryo.jp/section/index.html

Email

hidemasa@md.okayama-u.ac.jp


Sponsor or person

Institute

Okayama University Hospital

Institute

Department

Personal name



Funding Source

Organization

Okayama University Hospital

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Translational Research Informatics Center

Name of secondary funder(s)

Ministry of Health, labour and Welfare


IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

岡山大学病院(岡山市)


Other administrative information

Date of disclosure of the study information

2013 Year 04 Month 10 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2012 Year 12 Month 03 Day

Date of IRB


Anticipated trial start date

2013 Year 04 Month 15 Day

Last follow-up date

2016 Year 03 Month 31 Day

Date of closure to data entry

2016 Year 06 Month 30 Day

Date trial data considered complete

2016 Year 08 Month 31 Day

Date analysis concluded

2016 Year 09 Month 30 Day


Other

Other related information



Management information

Registered date

2013 Year 04 Month 09 Day

Last modified on

2017 Year 01 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012219


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name